NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016
Go back to NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016| NEOGENOMICS (NASDAQ: NEO) | Delayed: 11.47 +0.27 (2.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.20 | 52 Week High | $9.54 | |||
| Open | $11.14 | 52 Week Low | $5.49 | |||
| Day High | $11.68 | P/E | 286.75 | |||
| Day Low | $11.13 | EPS | $0.04 | |||
| Volume | 3,499,434 | |||||
